These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 37453930)

  • 1. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events.
    Meybodi SM; Farasati Far B; Pourmolaei A; Baradarbarjastehbaf F; Safaei M; Mohammadkhani N; Samadani AA
    Med Oncol; 2023 Jul; 40(8):243. PubMed ID: 37453930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in the Treatment of Cancer.
    Zam W; Ali L
    Curr Rev Clin Exp Pharmacol; 2022; 17(2):103-113. PubMed ID: 33823768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
    Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors in Cancer Therapy.
    Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
    Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy.
    Guo R; Li J; Hu J; Fu Q; Yan Y; Xu S; Wang X; Jiao F
    Int Immunopharmacol; 2023 Jul; 120():110417. PubMed ID: 37276826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Qiu J; Cheng Z; Jiang Z; Gan L; Zhang Z; Xie Z
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
    Kooshkaki O; Derakhshani A; Hosseinkhani N; Torabi M; Safaei S; Brunetti O; Racanelli V; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.
    Kong Q; Wang H; Ren X; Zhuo Y; Peng J
    Cancer Med; 2023 Oct; 12(19):19491-19499. PubMed ID: 37724594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
    Lu C; Tan Y
    Mol Ther Oncol; 2024 Mar; 32(1):200773. PubMed ID: 38596295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4.
    Parvini S; Majidpoor J; Mortezaee K
    Pathol Res Pract; 2023 Jul; 247():154583. PubMed ID: 37267723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.